Surveys assess access to morbidity management and disability prevention in lymphatic filariasis cases, highlighting low awareness and treatment reach.
The Global Program to Eliminate Lymphatic Filariasis (LF) aims to eliminate transmission through mass drug administration (MDA) and manage LF disease through morbidity management and disability prevention (MMDP). In this study, surveys on awareness and access to MMDP and quality of life (QoL) among lower limb LF cases in a censused population in two post-MDA districts in Tamil Nadu were conducted. The prevalence of lower limb LF was 0.11% (165/147,871), with 57.6% in reversible stage 1 and 2 categories, 36.4% in stage 3, and 6.1% in stage 4 and above. Among them, 22.4% reported health worker visits, 11.5% were aware of MMDP camps, and 36.4% received MMDP kits. The life activity (mean score: 48.5; SD: 27.3) and mobility (41.2; 24.2) domains exhibited the poorest QoL scores. In post-MDA districts, strengthening the reach and awareness of MMDP programs in communities, especially for early, reversible stages, is pivotal to halting disease progression and improving QoL.
No takes yet. Share an insight, caveat, or question.
Jog et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: